Literature DB >> 9130035

The benefits of modest weight loss in type II diabetes.

O Bosello1, F Armellini, M Zamboni, M Fitchet.   

Abstract

Obesity increases the risk of developing type II diabetes. However, the link between the two remains unclear, although insulin resistance and visceral adiposity are dominant risk factors. A study with CT scanning confirmed that the degree of visceral adiposity had a significant positive correlation with insulinaemia, and was negatively associated with insulin sensitivity. A 48 month retrospective study in patients with type II diabetes, who had received dietary therapy, identified a 'responder' group in whom metabolic improvements accompanied weight loss. Preferential loss of visceral fat may be an important factor in these 'responders'. Patients losing > 6.9 kg (or at least 10% mean baseline body weight) have demonstrated significant improvements in their glucose, HbA1 and lipid profiles. Modest weight loss by patients with type II diabetes therefore improves glycaemic control, insulin sensitivity and cardiovascular risk factors; and the risk of developing long-term diabetes-related complications may also be reduced by such metabolic improvements.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9130035

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  17 in total

Review 1.  Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action.

Authors:  J Grams; W Timothy Garvey
Journal:  Curr Obes Rep       Date:  2015-06

2.  Neutralizing circulating ghrelin by expressing a growth hormone secretagogue receptor-based protein protects against high-fat diet-induced obesity in mice.

Authors:  J Gagnon; L Zhu; Y Anini; Q Wang
Journal:  Gene Ther       Date:  2015-06-25       Impact factor: 5.250

3.  Preoperative weight gain might increase risk of gastric bypass surgery.

Authors:  Nawfal W Istfan; Wendy A Anderson; Caroline M Apovian; Donald T Hess; R Armour Forse
Journal:  Surg Obes Relat Dis       Date:  2010-09-17       Impact factor: 4.734

Review 4.  Sibutramine lost and found.

Authors:  O Bosello; M O Carruba; E Ferrannini; C M Rotella
Journal:  Eat Weight Disord       Date:  2002-09       Impact factor: 4.652

5.  Randomized double-blind placebo-controlled trial of powdered Brassica rapa ethanol extract on alteration of body composition and plasma lipid and adipocytokine profiles in overweight subjects.

Authors:  Seon-Min Jeon; Ji-Eun Kim; Su-Kyung Shin; Eun-Young Kwon; Un Ju Jung; Nam-In Baek; Kyung-Tae Lee; Tae-Sook Jeong; Hae-Gon Chung; Myung-Sook Choi
Journal:  J Med Food       Date:  2013-01-23       Impact factor: 2.786

Review 6.  Management of the metabolic syndrome and type 2 diabetes through lifestyle modification.

Authors:  Faidon Magkos; Mary Yannakoulia; Jean L Chan; Christos S Mantzoros
Journal:  Annu Rev Nutr       Date:  2009       Impact factor: 11.848

Review 7.  Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?

Authors:  André J Scheen
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  The effect of weight loss on health, productivity, and medical expenditures among overweight employees.

Authors:  Marcel Bilger; Eric A Finkelstein; Eliza Kruger; Deborah F Tate; Laura A Linnan
Journal:  Med Care       Date:  2013-06       Impact factor: 2.983

Review 9.  Current management strategies for coexisting diabetes mellitus and obesity.

Authors:  Andre J Scheen
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 10.  A benefit-risk assessment of sibutramine in the management of obesity.

Authors:  Enzo Nisoli; Michele O Carruba
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.